Ultragenyx RARE Crashes 47% on Angelman Trial…

Ultragenyx Pharmaceutical shares collapsed nearly 47% after apazunersen failed every endpoint in the Phase 3 Aspire Angelman study, erasing $1.14 billion in market value and forcing a strategic overhaul.

Apazunersen (GTX-102) showed zero separation from placebo on the primary Bayley-4 cognitive endpoint and all five components of the secondary Multidomain Responder Index.
Ultragenyx lost $1.14 billion in market capitalization; at least five brokerages downgraded the stock or cut price targets by 50% or more.
The company will pursue sweeping expense reductions and conduct a full pipeline review while targeting a return to profitability in 2027.

Lead

Ultragenyx Pharmaceutical (RARE) announced September 2, 2026 that apazunersen, also designated GTX-102, had failed to beat placebo on any measured endpoint in the Phase 3 Aspire study in Angelman syndrome patients, sending shares down 44.7% to $14.67 in premarket trading and eliminating what had been the company's most closely watched pipeline asset. The 129-patient trial - involving children and adolescents ages 4 to 17 with genetically confirmed Angelman syndrome from full maternal UBE3A gene deletion - enrolled participants in a 1:1 randomization between intrathecal GTX-102 and a sham control over 48 weeks.

What Did the Aspire Trial Actually Find?

The Phase 3 Aspire study found no meaningful improvement in apazunersen-treated patients over the sham control arm on any measure. The primary endpoint, change from baseline in the Bayley Scales of Infant and Toddler Development Fourth Edition (Bayley-4) cognitive raw score, showed no statistical separation. The key secondary endpoint, net response rate on the Multidomain Responder Index (MDRI), likewise failed to differentiate between arms, with no signal on any of the five individual MDRI components including cognition and receptive communication. The safety profile in Phase 3 remained consistent with earlier-stage data, removing safety concerns as an explanation for the null result.

Why Did RARE Stock Fall So Sharply?

The collapse reflects apazunersen's outsized weight in Ultragenyx's valuation. The drug had generated significant investor confidence following an April 2024 Phase 1/2 interim readout that showed rapid and clinically significant improvement in Bayley-4 cognition scores relative to natural history data alongside behavioral gains. The Phase 3 failure eliminated not just a near-term revenue pathway but the company's primary argument for premium growth valuation in biotech company stocks of its size. With the pipeline now stripped of its lead rare disease catalyst, the market re-rated RARE against its current commercial base, which is generating revenue but not yet generating net income.

Analyst Reaction and Market Impact

Downgrades and price target reductions arrived in waves. JPMorgan cut RARE to Neutral from Overweight, slashing its price target to $36 from $80. Evercore ISI moved to In Line from Outperform, targeting $16 versus the prior $34. Baird downgraded to Neutral, cutting to $16 from $40. Wells Fargo reduced its target to $18 from $50. Canaccord maintained a Buy but lowered its target to $37 from $83. At least two additional brokerages adjusted estimates following the announcement. The collective message: Aspire does not represent a data anomaly that can be explained away - it signals that the Phase 1/2 signals did not translate into confirmatory Phase 3 evidence, a recurring challenge in rare neurodevelopmental disease development.

Strategic Fallout and What Comes Next for Ultragenyx

Management will evaluate the apazunersen program before making a formal disposition decision - whether to discontinue, partner, or explore further study in subpopulations. In parallel, Ultragenyx committed to assessing planned operations and implementing significant expense reductions, a phrase the company has not previously used in recent quarters. The commercial portfolio, including the recently approved GENGLYCOS for glycogen storage disease type Ia and the pending regulatory review of UX111 for Sanfilippo syndrome, provides revenue continuity. The company reiterated a 2027 profitability target, though the path becomes narrower absent the revenue potential apazunersen would have represented.

Outlook

Ultragenyx faces a fundamental reset. Removing apazunersen from the pipeline - the catalyst that justified much of its growth premium - compresses the near-term revenue opportunity and forces a tighter focus on its existing approved products and late-stage assets. Expense reductions narrow cash burn while the strategic review plays out, but the company must now demonstrate that its remaining pipeline justifies a market capitalization that, even after the crash, sits above $2.6 billion. The 2027 profitability target hinges on commercial execution without GTX-102's contribution. Investors will watch for clarity on the scale of cost cuts and whether any pipeline additions or partnerships emerge in coming quarters.